The Relationship Between Alzheimer’s Disease and Skin Diseases: A Review

References

• Zhang H, Chen K, Wang N, et al. Analysis of brain donors’ demographic and medical characteristics to facilitate the construction of a human brain bank in China. J Alzheimers Dis. 2018;66(3):1245–1254. doi:10.3233/JAD-180779
   Web of Science ®Google Scholar
• Goodman RA, Lochner KA, Thambisetty M, Wingo TS, Posner SF, Ling SM. Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011–2013. Alzheimers Dement. 2017;13(1):28–37. doi:10.1016/j.jalz.2016.04.002
   PubMed Web of Science ®Google Scholar
• Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer’s disease. Lancet. 2021;397(10284):1577–1590. doi:10.1016/S0140-6736(20)32205-4
   PubMed Web of Science ®Google Scholar
• Clos AL, Kayed R, Lasagna-Reeves CA. Association of skin with the pathogenesis and treatment of neurodegenerative amyloidosis. Front Neurol. 2012;3:5. doi:10.3389/fneur.2012.00005
   Google Scholar
• Akerman SC, Hossain S, Shobo A, et al. Neurodegenerative disease-related proteins within the epidermal layer of the human skin. J Alzheimers Dis. 2019;69(2):463–478. doi:10.3233/JAD-181191
   Web of Science ®Google Scholar
• Försti AK, Jokelainen J, Ansakorpi H, et al. Psychiatric and neurological disorders are associated with bullous pemphigoid - a nationwide Finnish Care Register study. Sci Rep. 2016;6:37125. doi:10.1038/srep37125
   Web of Science ®Google Scholar
• White RS, Lipton RB, Hall CB, Steinerman JR. Nonmelanoma skin cancer is associated with reduced Alzheimer disease risk. Neurology. 2013;80(21):1966–1972. doi:10.1212/WNL.0b013e3182941990
   Web of Science ®Google Scholar
• Kluger N, Pankakoski A, Panelius J. Depression and anxiety in patients with bullous pemphigoid: impact and management challenges. Clin Cosmet Investig Dermatol. 2020;13:73–76. doi:10.2147/CCID.S212984
   Web of Science ®Google Scholar
• Delli FS, Sotiriou E, Lazaridou E, et al. Total IgE, eosinophils, and interleukins 16, 17A, and 23 correlations in severe bullous pemphigoid and treatment implications. Dermatol Ther. 2020;33(6):e13958. doi:10.1111/dth.13958
   Web of Science ®Google Scholar
• Azimi SZ, Firooz A, Murrell DF, Daneshpazhooh M. Treatment concerns for bullous pemphigoid in the COVID-19 pandemic era. Dermatol Ther. 2020;33(6):e13956. doi:10.1111/dth.13956
   Web of Science ®Google Scholar
• Wang YN, Hammers CM, Mao X, Jin HZ, Yuan J, Li L. Analysis of the autoimmune response against BP180 in patients with Alzheimer’s disease. Ann Transl Med. 2021;9(2):107. doi:10.21037/atm-20-5343
   PubMed Web of Science ®Google Scholar
• Zhao W, Wang Y, Mao X, et al. Detection of underlying dementia in bullous pemphigoid patients using cognitive evaluation tests: a multicenter case-control study. Ann Transl Med. 2020;8(21):1397. doi:10.21037/atm-20-1319
   PubMed Web of Science ®Google Scholar
• Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320–332. doi:10.1016/S0140-6736(12)61140-4
   PubMed Web of Science ®Google Scholar
• Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol. 2011;131(3):631–636. doi:10.1038/jid.2010.357
   PubMed Web of Science ®Google Scholar
• Lai YC, Yew YW, Lambert WC. Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2016;30(12):2007–2015. doi:10.1111/jdv.13660
   Web of Science ®Google Scholar
• Taghipour K, Chi CC, Vincent A, Groves RW, Venning V, Wojnarowska F. The association of bullous pemphigoid with cerebrovascular disease and dementia: a case-control study. Arch Dermatol. 2010;146(11):1251–1254. doi:10.1001/archdermatol.2010.322
   PubMedGoogle Scholar
• Messingham KN, Miller AD, Narayanan NS, Connell SJ, Fairley JA. Demographics and autoantibody profiles of pemphigoid patients with underlying neurologic diseases. J Invest Dermatol. 2019;139(9):1860–1866. doi:10.1016/j.jid.2019.01.034
   Web of Science ®Google Scholar
• Bastuji-Garin S, Joly P, Lemordant P, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol. 2011;131(3):637–643. doi:10.1038/jid.2010.301
   PubMed Web of Science ®Google Scholar
• Chen YJ, Wu CY, Lin MW, et al. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol. 2011;165(3):593–599. doi:10.1111/j.1365-2133.2011.10386.x
   PubMed Web of Science ®Google Scholar
• Brick KE, Weaver CH, Savica R, et al. A population-based study of the association between bullous pemphigoid and neurologic disorders. J Am Acad Dermatol. 2014;71(6):1191–1197. doi:10.1016/j.jaad.2014.07.052
   Web of Science ®Google Scholar
• Kibsgaard L, Rasmussen M, Lamberg A, Deleuran M, Olesen AB, Vestergaard C. Increased frequency of multiple sclerosis among patients with bullous pemphigoid: a population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid. Br J Dermatol. 2017;176(6):1486–1491. doi:10.1111/bjd.15405
   Web of Science ®Google Scholar
• Papakonstantinou E, Limberg MM, Gehring M, et al. Neurological disorders are associated with bullous pemphigoid. J Eur Acad Dermatol Venereol. 2019;33(5):925–929. doi:10.1111/jdv.15444
   PubMed Web of Science ®Google Scholar
• Seppänen A, Suuronen T, Hofmann SC, Majamaa K, Alafuzoff I. Distribution of collagen XVII in the human brain. Brain Res. 2007;1158:50–56. doi:10.1016/j.brainres.2007.04.073
   PubMed Web of Science ®Google Scholar
• Seppänen A, Autio-Harmainen H, Alafuzoff I, et al. Collagen XVII is expressed in human CNS neurons. Matrix Biol. 2006;25(3):185–188. doi:10.1016/j.matbio.2005.11.004
   Web of Science ®Google Scholar
• Kridin K, Hübner F, Recke A, Linder R, Schmidt E. The burden of neurological comorbidities in six autoimmune bullous diseases: a population-based study. J Eur Acad Dermatol Venereol. 2021. doi:10.1111/jdv.17465
   Web of Science ®Google Scholar
• Seppänen A. Collagen XVII: a shared antigen in neurodermatological interactions? Clin Dev Immunol. 2013;2013:240570. doi:10.1155/2013/240570
   Google Scholar
• Chen J, Li L, Chen J, et al. Sera of elderly bullous pemphigoid patients with associated neurological diseases recognize bullous pemphigoid antigens in the human brain. Gerontology. 2011;57(3):211–216. doi:10.1159/000315393
   Web of Science ®Google Scholar
• Kokkonen N, Herukka SK, Huilaja L, et al. Increased levels of the bullous pemphigoid BP180 autoantibody are associated with more severe dementia in Alzheimer’s disease. J Invest Dermatol. 2017;137(1):71–76. doi:10.1016/j.jid.2016.09.010
   PubMed Web of Science ®Google Scholar
• Messingham KAN, Aust S, Helfenberger J, et al. Autoantibodies to collagen XVII are present in Parkinson’s disease and localize to tyrosine-hydroxylase positive neurons. J Invest Dermatol. 2016;136(3):721–723. doi:10.1016/j.jid.2015.12.005
   PubMed Web of Science ®Google Scholar
• Recke A, Oei A, Hübner F, et al. Parkinson disease and multiple sclerosis are not associated with autoantibodies against structural proteins of the dermal-epidermal junction. Br J Dermatol. 2016;175(2):407–409. doi:10.1111/bjd.14538
   Web of Science ®Google Scholar
• Barrick BJ, Ida CM, Laniosz V, et al. Bullous pemphigoid, neurodegenerative disease, and hippocampal BP180 expression: a retrospective postmortem neuropathologic study. J Invest Dermatol. 2016;136(10):2090–2092. doi:10.1016/j.jid.2016.06.015
   Web of Science ®Google Scholar
• Künzli K, Favre B, Chofflon M, Borradori L. One gene but different proteins and diseases: the complexity of dystonin and bullous pemphigoid antigen 1. Exp Dermatol. 2016;25(1):10–16. doi:10.1111/exd.12877
   Web of Science ®Google Scholar
• Tuusa J, Lindgren O, Tertsunen HM, et al. BP180 autoantibodies target different epitopes in multiple sclerosis or Alzheimer’s disease than in bullous pemphigoid. J Invest Dermatol. 2019;139(2):293–299. doi:10.1016/j.jid.2018.09.010
   Web of Science ®Google Scholar
• Amber KT, Zikry J, Hertl M. A multi-hit hypothesis of bullous pemphigoid and associated neurological disease: is HLA-DQB1*03:01, a potential link between immune privileged antigen exposure and epitope spreading? Hla. 2017;89(3):127–134. doi:10.1111/tan.12960
   Web of Science ®Google Scholar
• Koumaki D, Efthymiou O, Bozi E, Katoulis AC. Perspectives on perceived stigma and self-stigma in patients with hidradenitis suppurativa. Clin Cosmet Investig Dermatol. 2019;12:785–790. doi:10.2147/CCID.S180036
   PubMed Web of Science ®Google Scholar
• Fernandez JM, Marr KD, Hendricks AJ, et al. Alleviating and exacerbating foods in hidradenitis suppurativa. Dermatol Ther. 2020;33(6):e14246. doi:10.1111/dth.14246
   Web of Science ®Google Scholar
• Misitzis A, Goldust M, Jafferany M, Lotti T. Psychiatric comorbidities in patients with hidradenitis suppurativa. Dermatol Ther. 2020;33(4):e13541. doi:10.1111/dth.13541
   Web of Science ®Google Scholar
• Shah M, Sachdeva M, Melendez-Gonzalez M, Piguet V, Sayed C. Hidradenitis suppurativa and chromosomal abnormalities: a case report and systematic review of the literature. Int J Dermatol. 2021;60(3):261–271. doi:10.1111/ijd.15111
   Web of Science ®Google Scholar
• Sabat R, Jemec GBE, Matusiak Ł, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18. doi:10.1038/s41572-020-0149-1
   PubMed Web of Science ®Google Scholar
• Nguyen TV, Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2021;35(1):50–61. doi:10.1111/jdv.16677
   PubMed Web of Science ®Google Scholar
• De Strooper B, Iwatsubo T, Wolfe MS. Presenilins and γ-secretase: structure, function, and role in Alzheimer Disease. Cold Spring Harb Perspect Med. 2012;2(1):a006304. doi:10.1101/cshperspect.a006304
   PubMed Web of Science ®Google Scholar
• Ingram JR. The genetics of hidradenitis suppurativa. Dermatol Clin. 2016;34(1):23–28. doi:10.1016/j.det.2015.07.002
   PubMed Web of Science ®Google Scholar
• Panza F, Frisardi V, Imbimbo BP, et al. REVIEW: γ-Secretase inhibitors for the treatment of Alzheimer’s disease: the current state. CNS Neurosci Ther. 2010;16(5):272–284. doi:10.1111/j.1755-5949.2010.00164.x
   Web of Science ®Google Scholar
• Xia X, Qian S, Soriano S, et al. Loss of presenilin 1 is associated with enhanced beta-catenin signaling and skin tumorigenesis. Proc Natl Acad Sci U S A. 2001;98(19):10863–10868. doi:10.1073/pnas.191284198
   PubMed Web of Science ®Google Scholar
• Pan Y, Lin MH, Tian X, et al. γ-Secretase functions through notch signaling to maintain skin appendages but is not required for their patterning or initial morphogenesis. Dev Cell. 2004;7(5):731–743. doi:10.1016/j.devcel.2004.09.014
   Web of Science ®Google Scholar
• Li T, Wen H, Brayton C, et al. Epidermal growth factor receptor and notch pathways participate in the tumor suppressor function of γ-secretase. J Biol Chem. 2007;282(44):32264–32273. doi:10.1074/jbc.M703649200
   Web of Science ®Google Scholar
• Girouard SD, Falk RH, Rennke HG, Merola JF. Hidradenitis suppurativa resulting in systemic amyloid A amyloidosis: a case report and review of the literature. Dermatol Online J. 2012;18(1):2. doi:10.5070/D30P46V20Q
   Google Scholar
• Canoui-Poitrine F, Le Thuaut A, Revuz JE, et al. Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. J Invest Dermatol. 2013;133(6):1506–1511. doi:10.1038/jid.2012.472
   PubMed Web of Science ®Google Scholar
• Ingram JR, Piguet V. Phenotypic heterogeneity in hidradenitis suppurativa (acne inversa): classification is an essential step toward personalized therapy. J Invest Dermatol. 2013;133(6):1453–1456. doi:10.1038/jid.2012.476
   PubMed Web of Science ®Google Scholar
• Pink AE, Simpson MA, Desai N, et al. Mutations in the γ-secretase genes NCSTN, PSENEN, and PSEN1 underlie rare forms of hidradenitis suppurativa (acne inversa). J Invest Dermatol. 2012;132(10):2459–2461. doi:10.1038/jid.2012.162
   PubMed Web of Science ®Google Scholar
• Ingram JR, Wood M, John B, Butler R, Anstey AV. Absence of pathogenic γ-secretase mutations in a South Wales cohort of familial and sporadic hidradenitis suppurativa (acne inversa). Br J Dermatol. 2013;168(4):874–876. doi:10.1111/bjd.12048
   Web of Science ®Google Scholar
• Nomura Y, Nomura T, Suzuki S, et al. A novel NCSTN mutation alone may be insufficient for the development of familial hidradenitis suppurativa. J Dermatol Sci. 2014;74(2):180–182. doi:10.1016/j.jdermsci.2014.01.013
   PubMed Web of Science ®Google Scholar
• Garg A, Strunk A. Risk of Alzheimer’s disease is not increased among patients with hidradenitis suppurativa: a retrospective population-based cohort analysis. J Am Acad Dermatol. 2017;77(1):176–177. doi:10.1016/j.jaad.2017.02.055
   Web of Science ®Google Scholar
• Theut Riis P, Egeberg A, Gislason GH, Jemec GB. Patients with hidradenitis suppurativa have no increased risk of Alzheimer disease. Br J Dermatol. 2017;177(1):273–275. doi:10.1111/bjd.15064
   Web of Science ®Google Scholar
• Frew JW, Vekic DA, Woods J, Cains GD. A systematic review and critical evaluation of reported pathogenic sequence variants in hidradenitis suppurativa. Br J Dermatol. 2017;177(4):987–998. doi:10.1111/bjd.15441
   PubMed Web of Science ®Google Scholar
• Frew JW, Navrazhina K. In silico analysis of gamma-secretase-complex mutations in hidradenitis suppurativa demonstrates disease-specific substrate recognition and cleavage alterations. Front Med. 2019;6:206. doi:10.3389/fmed.2019.00206
   Web of Science ®Google Scholar
• Li A, Peng Y, Taiclet LM, Tanzi RE. Analysis of hidradenitis suppurativa-linked mutations in four genes and the effects of PSEN1-P242LfsX11 on cytokine and chemokine expression in macrophages. Hum Mol Genet. 2019;28(7):1173–1182. doi:10.1093/hmg/ddy414
   Web of Science ®Google Scholar
• Esme P, Esme M, Caliskan E. Increased prevalence of family history of Alzheimer’s disease in hidradenitis suppurativa: cross-sectional analysis of 192 HS patients. Dermatol Ther. 2020;33(6):e14219. doi:10.1111/dth.14219
   Web of Science ®Google Scholar
• Nada EA, Muhammad EMS, Ahmed SFM, Tamam AMS, Abdelhamed A. Assessment of the effect of metabolic syndrome on the autophagy marker LC3 in psoriasis vulgaris patients: a cross-sectional study. Clin Cosmet Investig Dermatol. 2020;13:1005–1013. doi:10.2147/CCID.S284300
   Web of Science ®Google Scholar
• Carrascosa JM, Theng C, Thaçi D. Spotlight on topical long-term management of plaque psoriasis. Clin Cosmet Investig Dermatol. 2020;13:495–498. doi:10.2147/CCID.S254114
   PubMed Web of Science ®Google Scholar
• Fu Y, Lee CH, Chi CC. Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis. JAMA Dermatol. 2018;154(12):1417–1423. doi:10.1001/jamadermatol.2018.3631
   PubMed Web of Science ®Google Scholar
• Soliman M. Patient-reported disease severity and quality of life among Arabic psoriatic patients: a cross-sectional survey. Clin Cosmet Investig Dermatol. 2020;13:601–609. doi:10.2147/CCID.S269909
   Web of Science ®Google Scholar
• Ezzedine K, Fougerousse AC, Aubert R, et al. Individual burden of psoriasis (I-BOP): building and validation of a new scoring tool for patients with psoriasis. Clin Cosmet Investig Dermatol. 2020;13:325–332. doi:10.2147/CCID.S249776
   Web of Science ®Google Scholar
• Orrell KA, Vakharia PP, Hagstrom EL, Brieva J, West DP, Nardone B. Prevalence of chronic hepatitis B and C in psoriasis patients: a cross-sectional study in a large US population. J Am Acad Dermatol. 2017;77(3):572–573. doi:10.1016/j.jaad.2017.05.020
   PubMed Web of Science ®Google Scholar
• Leisner MZ, Riis JL, Schwartz S, Iversen L, Østergaard SD, Olsen MS. Psoriasis and risk of mental disorders in Denmark. JAMA Dermatol. 2019;155(6):745–747. doi:10.1001/jamadermatol.2019.0039
   PubMed Web of Science ®Google Scholar
• Kim M, Park HE, Lee SH, Han K, Lee JH. Increased risk of Alzheimer’s disease in patients with psoriasis: a nationwide population-based cohort study. Sci Rep. 2020;10(1):6454. doi:10.1038/s41598-020-63550-2
   PubMed Web of Science ®Google Scholar
• Huang KL, Yeh CC, Wu SI, et al. Risk of dementia among individuals with psoriasis: a nationwide population-based cohort study in Taiwan. J Clin Psychiatry. 2019;80(3):18m12462. doi:10.4088/JCP.18m12462
   Web of Science ®Google Scholar
• Lin CC, Lin HC, Chiu HW. Association between psoriasis and dementia: a population-based case-control study. Am J Clin Dermatol. 2019;20(3):457–463. doi:10.1007/s40257-018-00420-8
   PubMed Web of Science ®Google Scholar
• Pezzolo E, Mutlu U, Vernooij MW, et al. Psoriasis is not associated with cognition, brain imaging markers and risk of dementia: the Rotterdam Study. J Am Acad Dermatol. 2018. doi:10.1016/j.jaad.2018.07.046
   Web of Science ®Google Scholar
• Liu L, Chen ST, Li HJ, et al. Association between psoriasis and dementia: current evidence. Front Aging Neurosci. 2020;12:570992. doi:10.3389/fnagi.2020.570992
   PubMed Web of Science ®Google Scholar
• Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010;163(3):586–592. doi:10.1111/j.1365-2133.2010.09941.x
   PubMed Web of Science ®Google Scholar
• Gisondi P, Sala F, Alessandrini F, et al. Mild cognitive impairment in patients with moderate to severe chronic plaque psoriasis. Dermatology. 2014;228(1):78–85. doi:10.1159/000357220
   Web of Science ®Google Scholar
• Colgecen E, Celikbilek A, Keskin DT. Cognitive impairment in patients with psoriasis: a cross-sectional study using the Montreal cognitive assessment. Am J Clin Dermatol. 2016;17(4):413–419. doi:10.1007/s40257-016-0187-3
   PubMed Web of Science ®Google Scholar
• Decourt B, Lahiri DK, Sabbagh MN. Targeting tumor necrosis factor alpha for Alzheimer’s disease. Curr Alzheimer Res. 2017;14(4):412–425. doi:10.2174/1567205013666160930110551
   PubMed Web of Science ®Google Scholar
• Zhou M, Xu R, Kaelber DC, Gurney ME. Tumor necrosis factor (TNF) blocking agents are associated with lower risk for Alzheimer’s disease in patients with rheumatoid arthritis and psoriasis. PLoS One. 2020;15(3):e0229819. doi:10.1371/journal.pone.0229819
   PubMed Web of Science ®Google Scholar
• Rich P, Bourcier M, Sofen H, et al. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. Br J Dermatol. 2014;170(2):398–407. doi:10.1111/bjd.12632
   PubMed Web of Science ®Google Scholar
• Mohammadi Shahrokhi V, Ravari A, Mirzaei T, Zare-Bidaki M, Asadikaram G, Arababadi MK. IL-17A and IL-23: plausible risk factors to induce age-associated inflammation in Alzheimer’s disease. Immunol Invest. 2018;47(8):812–822. doi:10.1080/08820139.2018.1504300
   PubMed Web of Science ®Google Scholar
• Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16(6):358–372. doi:10.1038/nrn3880
   PubMed Web of Science ®Google Scholar
• Vom Berg J, Prokop S, Miller KR, et al. Inhibition of IL-12/IL-23 signaling reduces Alzheimer’s disease-like pathology and cognitive decline. Nat Med. 2012;18(12):1812–1819. doi:10.1038/nm.2965
   PubMed Web of Science ®Google Scholar
• Belloy ME, Napolioni V, Greicius MD. A quarter century of APOE and Alzheimer’s disease: progress to date and the path forward. Neuron. 2019;101(5):820–838. doi:10.1016/j.neuron.2019.01.056
   PubMed Web of Science ®Google Scholar
• Al Harthi F, Huraib GB, Zouman A, Arfin M, Tariq M, Al-Asmari A. Apolipoprotein E gene polymorphism and serum lipid profile in Saudi patients with psoriasis. Dis Markers. 2014;2014:239645. doi:10.1155/2014/239645
   PubMed Web of Science ®Google Scholar
• Campalani E, Allen MH, Fairhurst D, et al. Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol. 2006;154(2):345–352. doi:10.1111/j.1365-2133.2005.06950.x
   PubMed Web of Science ®Google Scholar
• Han Y, Liu T, Lu L. Apolipoprotein E gene polymorphism in psoriasis: a meta-analysis. Arch Med Res. 2013;44(1):46–53. doi:10.1016/j.arcmed.2012.10.009
   PubMed Web of Science ®Google Scholar
• Coto-Segura P, Coto E, Alvarez V, et al. Apolipoprotein ε4 allele is associated with psoriasis severity. Arch Dermatol Res. 2010;302(2):145–149. doi:10.1007/s00403-009-1002-2
   Web of Science ®Google Scholar
• Yokoyama JS, Wang Y, Schork AJ, et al. Association between genetic traits for immune-mediated diseases and Alzheimer disease. JAMA Neurol. 2016;73(6):691–697. doi:10.1001/jamaneurol.2016.0150
   PubMed Web of Science ®Google Scholar
• Ospina-Romero M, Glymour MM, Hayes-Larson E, et al. Association between Alzheimer disease and cancer with evaluation of study biases: a systematic review and meta-analysis. JAMA Network Open. 2020;3(11):e2025515. doi:10.1001/jamanetworkopen.2020.25515
   Web of Science ®Google Scholar
• Roe CM, Fitzpatrick AL, Xiong C, et al. Cancer linked to Alzheimer disease but not vascular dementia. Neurology. 2010;74(2):106–112. doi:10.1212/WNL.0b013e3181c91873
   Web of Science ®Google Scholar
• Leiter U, Keim U, Garbe C. Epidemiology of skin cancer: update 2019. Adv Exp Med Biol. 2020;1268:123–139.
   PubMed Web of Science ®Google Scholar
• Schmidt SA, Ording AG, Horváth-Puhó E, Sørensen HT, Henderson VW. Non-melanoma skin cancer and risk of Alzheimer’s disease and all-cause dementia. PLoS One. 2017;12(2):e0171527. doi:10.1371/journal.pone.0171527
   PubMed Web of Science ®Google Scholar
• Ibler E, Tran G, Orrell KA, et al. Inverse association for diagnosis of Alzheimer’s disease subsequent to both melanoma and non-melanoma skin cancers in a large, urban, single-centre, Midwestern US patient population. J Eur Acad Dermatol Venereol. 2018;32(11):1893–1896. doi:10.1111/jdv.14952
   Web of Science ®Google Scholar
• Houck AL, Seddighi S, Driver JA. At the crossroads between neurodegeneration and cancer: a review of overlapping biology and its implications. Curr Aging Sci. 2018;11(2):77–89. doi:10.2174/1874609811666180223154436
   PubMedGoogle Scholar
• Nakanishi A, Minami A, Kitagishi Y, Ogura Y, Matsuda S. BRCA1 and p53 tumor suppressor molecules in Alzheimer’s disease. Int J Mol Sci. 2015;16(2):2879–2892. doi:10.3390/ijms16022879
   Web of Science ®Google Scholar
• Ma SL, Tang NL, Tam CW, et al. A PIN1 polymorphism that prevents its suppression by AP4 associates with delayed onset of Alzheimer’s disease. Neurobiol Aging. 2012;33(4):804–813. doi:10.1016/j.neurobiolaging.2010.05.018
   Web of Science ®Google Scholar
• Segat L, Pontillo A, Annoni G, et al. PIN1 promoter polymorphisms are associated with Alzheimer’s disease. Neurobiol Aging. 2007;28(1):69–74. doi:10.1016/j.neurobiolaging.2005.11.009
   Web of Science ®Google Scholar
• Kumar S, Reddy PH. A new discovery of MicroRNA-455-3p in Alzheimer’s disease. J Alzheimers Dis. 2019;72(s1):S117–s130. doi:10.3233/JAD-190583
   PubMed Web of Science ®Google Scholar
• Galvão F, Grokoski KC, da Silva BB, Lamers ML, Siqueira IR. The amyloid precursor protein (APP) processing as a biological link between Alzheimer’s disease and cancer. Ageing Res Rev. 2019;49:83–91. doi:10.1016/j.arr.2018.11.007
   Web of Science ®Google Scholar
• Botelho MG, Wang X, Arndt-Jovin DJ, Becker D, Jovin TM. Induction of terminal differentiation in melanoma cells on downregulation of β-amyloid precursor protein. J Invest Dermatol. 2010;130(5):1400–1410. doi:10.1038/jid.2009.296
   Web of Science ®Google Scholar
• Matafora V, Farris F, Restuccia U, et al. Amyloid aggregates accumulate in melanoma metastasis modulating YAP activity. EMBO Rep. 2020;21(9):e50446. doi:10.15252/embr.202050446
   Web of Science ®Google Scholar
• Cummings J. What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer’s disease? Biol Psychiatry. 2010;68(10):876–878. doi:10.1016/j.biopsych.2010.09.020
   Web of Science ®Google Scholar
• Li T, Wen H, Brayton C, et al. Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities. J Neurosci. 2007;27(40):10849–10859. doi:10.1523/JNEUROSCI.2152-07.2007
   Web of Science ®Google Scholar
• Ostendorf BN, Bilanovic J, Adaku N, et al. Common germline variants of the human APOE gene modulate melanoma progression and survival. Nat Med. 2020;26(7):1048–1053. doi:10.1038/s41591-020-0879-3
   PubMed Web of Science ®Google Scholar
• Lövdén M, Xu W, Wang HX. Lifestyle change and the prevention of cognitive decline and dementia: what is the evidence? Curr Opin Psychiatry. 2013;26(3):239–243. doi:10.1097/YCO.0b013e32835f4135
   PubMed Web of Science ®Google Scholar
• D’Orazio J, Jarrett S, Amaro-Ortiz A, Scott T. UV radiation and the skin. Int J Mol Sci. 2013;14(6):12222–12248. doi:10.3390/ijms140612222
   PubMed Web of Science ®Google Scholar
• Steding-Jessen M, Birch-Johansen F, Jensen A, Schüz J, Kjær SK, Dalton SO. Socioeconomic status and non-melanoma skin cancer: a nationwide cohort study of incidence and survival in Denmark. Cancer Epidemiol. 2010;34(6):689–695. doi:10.1016/j.canep.2010.06.011
   PubMed Web of Science ®Google Scholar
• Tillement JP, Lecanu L, Papadopoulos V. Amyloidosis and neurodegenerative diseases: current treatments and new pharmacological options. Pharmacology. 2010;85(1):1–17. doi:10.1159/000259044
   Web of Science ®Google Scholar
• Schreml S, Kaiser E, Landthaler M, Szeimies RM, Babilas P. Amyloid in skin and brain: what’s the link? Exp Dermatol. 2010;19(11):953–957. doi:10.1111/j.1600-0625.2010.01166.x
   Web of Science ®Google Scholar
• Awal G, Kaur S. Association of cutaneous amyloidosis with neurodegenerative amyloidosis: correlation or coincidence? J Clin Aesthet Dermatol. 2018;11(4):25–27.
   Google Scholar
• Chen G, Chen ZM, Fan XY, et al. Gut-brain-skin axis in psoriasis: a review. Dermatol Ther. 2021;11(1):25–38. doi:10.1007/s13555-020-00466-9
   Web of Science ®Google Scholar
• Neau JP, Godeneche G, Mathis S, Guillet G. Neurodermatology. Handb Clin Neurol. 2014;121:1561–1594.
   PubMedGoogle Scholar